Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company.
--------
12:26
--------
12:26
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
--------
5:11
--------
5:11
Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies
He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026.
--------
5:58
--------
5:58
Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all
CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.
--------
8:36
--------
8:36
Stifel's I&I expert Alex Thompson shares his take on the environment and discusses names he covers that have key catalyst events
He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka.
España